JP6843065B2 - リボ核酸の無細胞生産 - Google Patents
リボ核酸の無細胞生産 Download PDFInfo
- Publication number
- JP6843065B2 JP6843065B2 JP2017551594A JP2017551594A JP6843065B2 JP 6843065 B2 JP6843065 B2 JP 6843065B2 JP 2017551594 A JP2017551594 A JP 2017551594A JP 2017551594 A JP2017551594 A JP 2017551594A JP 6843065 B2 JP6843065 B2 JP 6843065B2
- Authority
- JP
- Japan
- Prior art keywords
- rna
- cell
- cell lysate
- cells
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920002477 rna polymer Polymers 0.000 title claims description 144
- 238000004519 manufacturing process Methods 0.000 title claims description 44
- 210000004027 cell Anatomy 0.000 claims description 186
- 238000000034 method Methods 0.000 claims description 122
- 239000013592 cell lysate Substances 0.000 claims description 112
- 150000007523 nucleic acids Chemical class 0.000 claims description 109
- 102000039446 nucleic acids Human genes 0.000 claims description 104
- 108020004707 nucleic acids Proteins 0.000 claims description 104
- 108091005804 Peptidases Proteins 0.000 claims description 73
- 239000004365 Protease Substances 0.000 claims description 73
- 101710163270 Nuclease Proteins 0.000 claims description 72
- 239000002773 nucleotide Substances 0.000 claims description 66
- 125000003729 nucleotide group Chemical group 0.000 claims description 58
- 102000053602 DNA Human genes 0.000 claims description 55
- 108020004414 DNA Proteins 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 45
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 45
- 230000008685 targeting Effects 0.000 claims description 41
- 102000004190 Enzymes Human genes 0.000 claims description 39
- 108090000790 Enzymes Proteins 0.000 claims description 39
- 102000006382 Ribonucleases Human genes 0.000 claims description 35
- 108010083644 Ribonucleases Proteins 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 24
- 108020004999 messenger RNA Proteins 0.000 claims description 22
- 108091000080 Phosphotransferase Proteins 0.000 claims description 21
- 102000020233 phosphotransferase Human genes 0.000 claims description 21
- 239000011541 reaction mixture Substances 0.000 claims description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 17
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 17
- 230000017854 proteolysis Effects 0.000 claims description 16
- 229920000137 polyphosphoric acid Polymers 0.000 claims description 15
- 102000001253 Protein Kinase Human genes 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 14
- 108060006633 protein kinase Proteins 0.000 claims description 14
- 230000001419 dependent effect Effects 0.000 claims description 13
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 108060004795 Methyltransferase Proteins 0.000 claims description 12
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 claims description 11
- 229920000388 Polyphosphate Polymers 0.000 claims description 11
- 102100034410 Polyribonucleotide nucleotidyltransferase 1, mitochondrial Human genes 0.000 claims description 11
- 239000001177 diphosphate Substances 0.000 claims description 11
- -1 nucleotide monophosphate Chemical class 0.000 claims description 11
- 239000001205 polyphosphate Substances 0.000 claims description 11
- 235000011176 polyphosphates Nutrition 0.000 claims description 11
- 206010061764 Chromosomal deletion Diseases 0.000 claims description 10
- 108010042407 Endonucleases Proteins 0.000 claims description 10
- 102000004533 Endonucleases Human genes 0.000 claims description 10
- 238000012258 culturing Methods 0.000 claims description 10
- 239000001226 triphosphate Substances 0.000 claims description 10
- 238000003776 cleavage reaction Methods 0.000 claims description 9
- 230000007017 scission Effects 0.000 claims description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 8
- 235000011180 diphosphates Nutrition 0.000 claims description 8
- 210000004748 cultured cell Anatomy 0.000 claims description 7
- 230000002779 inactivation Effects 0.000 claims description 7
- 101710137500 T7 RNA polymerase Proteins 0.000 claims description 6
- 108020000161 polyphosphate kinase Proteins 0.000 claims description 6
- 108091023030 exopolyphosphatase Proteins 0.000 claims description 5
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 claims description 4
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 4
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 4
- 230000002934 lysing effect Effects 0.000 claims description 4
- 239000002777 nucleoside Substances 0.000 claims description 4
- 102000002281 Adenylate kinase Human genes 0.000 claims description 3
- 108020000543 Adenylate kinase Proteins 0.000 claims description 3
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 3
- 108020004202 Guanylate Kinase Proteins 0.000 claims description 2
- 102100036518 Nucleoside diphosphate phosphatase ENTPD5 Human genes 0.000 claims description 2
- 108010044790 Nucleoside-Phosphate Kinase Proteins 0.000 claims description 2
- 102000005811 Nucleoside-phosphate kinase Human genes 0.000 claims description 2
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 claims description 2
- FOGRQMPFHUHIGU-UHFFFAOYSA-N Uridylic acid Natural products OC1C(OP(O)(O)=O)C(CO)OC1N1C(=O)NC(=O)C=C1 FOGRQMPFHUHIGU-UHFFFAOYSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 102000006638 guanylate kinase Human genes 0.000 claims description 2
- 108010028546 nucleoside-diphosphatase Proteins 0.000 claims description 2
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 15
- 102000035195 Peptidases Human genes 0.000 description 58
- 235000019419 proteases Nutrition 0.000 description 54
- 238000013518 transcription Methods 0.000 description 26
- 230000035897 transcription Effects 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 23
- 230000008569 process Effects 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 16
- 210000001322 periplasm Anatomy 0.000 description 13
- 230000015556 catabolic process Effects 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 238000012705 nitroxide-mediated radical polymerization Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000002336 ribonucleotide Substances 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108091028664 Ribonucleotide Proteins 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 125000002652 ribonucleotide group Chemical group 0.000 description 7
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 108091069025 single-strand RNA Proteins 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 108010002700 Exoribonucleases Proteins 0.000 description 4
- 102000004678 Exoribonucleases Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000006037 cell lysis Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 108010032819 exoribonuclease II Proteins 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 3
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 3
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 3
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 241000702217 Pseudomonas virus phi6 Species 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011031 large-scale manufacturing process Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000004712 monophosphates Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 241000589220 Acetobacter Species 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 241000588986 Alcaligenes Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000589151 Azotobacter Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010061765 Chromosomal mutation Diseases 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 241000589519 Comamonas Species 0.000 description 2
- 101001112318 Dictyostelium discoideum Nucleoside diphosphate kinase, cytosolic Proteins 0.000 description 2
- 101001112320 Dictyostelium discoideum Nucleoside diphosphate kinase, mitochondrial Proteins 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 101001128731 Homo sapiens Putative nucleoside diphosphate kinase Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 102100032116 Putative nucleoside diphosphate kinase Human genes 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 241000187560 Saccharopolyspora Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000723792 Tobacco etch virus Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 241000589634 Xanthomonas Species 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002457 bidirectional effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108700010839 phage proteins Proteins 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 101150018558 rnb gene Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000266272 Acidithiobacillus Species 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 102100038740 Activator of RNA decay Human genes 0.000 description 1
- 108010075409 Alanine carboxypeptidase Proteins 0.000 description 1
- 108030000961 Aminopeptidase Y Proteins 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 244000221226 Armillaria mellea Species 0.000 description 1
- 235000011569 Armillaria mellea Nutrition 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010066768 Bacterial leucyl aminopeptidase Proteins 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 241001453380 Burkholderia Species 0.000 description 1
- 102100029226 Cancer-related nucleoside-triphosphatase Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 241000863012 Caulobacter Species 0.000 description 1
- 241000588881 Chromobacterium Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 108030000958 Cytosol alanyl aminopeptidases Proteins 0.000 description 1
- 239000005696 Diammonium phosphate Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000626621 Geobacillus Species 0.000 description 1
- 241001135750 Geobacter Species 0.000 description 1
- 241000589236 Gluconobacter Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001929 Lactobacillus brevis Species 0.000 description 1
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 108030007165 Leucyl endopeptidases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 1
- 102000034452 Methionyl aminopeptidases Human genes 0.000 description 1
- 241000589344 Methylomonas Species 0.000 description 1
- 241001148170 Microlunatus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229940122426 Nuclease inhibitor Drugs 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 241000520272 Pantoea Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101710135451 Probable cytidylate kinase Proteins 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 102100033192 Puromycin-sensitive aminopeptidase Human genes 0.000 description 1
- 108090000944 RNA Helicases Proteins 0.000 description 1
- 102000004409 RNA Helicases Human genes 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000232299 Ralstonia Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000589180 Rhizobium Species 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108090000638 Ribonuclease R Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- 241000122971 Stenotrophomonas Species 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 108030000963 Tryptophanyl aminopeptidases Proteins 0.000 description 1
- 108020000553 UMP kinase Proteins 0.000 description 1
- 102100020797 UMP-CMP kinase Human genes 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 102100029150 Uridine-cytidine kinase 2 Human genes 0.000 description 1
- 108030004686 Xaa-Pro aminopeptidases Proteins 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092259 cell-free RNA Proteins 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 108010032573 degradosome Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 229910000388 diammonium phosphate Inorganic materials 0.000 description 1
- 235000019838 diammonium phosphate Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012526 feed medium Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000530 impalefection Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 101150035025 lysC gene Proteins 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- QWLHYYKDLOVBNV-UHFFFAOYSA-L magnesium orotate Chemical compound [Mg+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QWLHYYKDLOVBNV-UHFFFAOYSA-L 0.000 description 1
- 229960000407 magnesium orotate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 239000006012 monoammonium phosphate Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 101150037544 pnp gene Proteins 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 108090000589 ribonuclease E Proteins 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004861 thermometry Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1247—DNA-directed RNA polymerase (2.7.7.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/10—Nucleotidyl transfering
- C12Q2521/119—RNA polymerase
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021026113A JP2021100406A (ja) | 2015-03-30 | 2021-02-22 | リボ核酸の無細胞生産 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140407P | 2015-03-30 | 2015-03-30 | |
| US62/140,407 | 2015-03-30 | ||
| PCT/US2016/024937 WO2016160936A1 (en) | 2015-03-30 | 2016-03-30 | Cell-free production of ribonucleic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021026113A Division JP2021100406A (ja) | 2015-03-30 | 2021-02-22 | リボ核酸の無細胞生産 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018509927A JP2018509927A (ja) | 2018-04-12 |
| JP2018509927A5 JP2018509927A5 (enExample) | 2019-05-09 |
| JP6843065B2 true JP6843065B2 (ja) | 2021-03-17 |
Family
ID=57007296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551594A Expired - Fee Related JP6843065B2 (ja) | 2015-03-30 | 2016-03-30 | リボ核酸の無細胞生産 |
| JP2021026113A Pending JP2021100406A (ja) | 2015-03-30 | 2021-02-22 | リボ核酸の無細胞生産 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021026113A Pending JP2021100406A (ja) | 2015-03-30 | 2021-02-22 | リボ核酸の無細胞生産 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11274284B2 (enExample) |
| EP (1) | EP3277808A4 (enExample) |
| JP (2) | JP6843065B2 (enExample) |
| KR (2) | KR20180002636A (enExample) |
| CN (1) | CN107614682B (enExample) |
| AU (1) | AU2016243623B2 (enExample) |
| BR (1) | BR112017020690A2 (enExample) |
| CA (1) | CA2980172A1 (enExample) |
| CL (1) | CL2017002427A1 (enExample) |
| CR (1) | CR20170485A (enExample) |
| IL (1) | IL254413B (enExample) |
| MX (1) | MX392776B (enExample) |
| MY (1) | MY193444A (enExample) |
| RU (1) | RU2017137788A (enExample) |
| SG (1) | SG11201707370WA (enExample) |
| WO (1) | WO2016160936A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2839424T3 (es) | 2010-08-31 | 2021-07-05 | Greenlight Biosciences Inc | Métodos para control de flujo en vías metabólicas mediante manipulación de proteasas |
| SG11201600898YA (en) | 2013-08-05 | 2016-03-30 | Greenlight Biosciences Inc | Engineered proteins with a protease cleavage site |
| EP3277808A4 (en) | 2015-03-30 | 2019-05-22 | Greenlight Biosciences, Inc. | ACELLULAR PRODUCTION OF RIBONUCLEIC ACID |
| AU2016256579B2 (en) * | 2015-04-30 | 2021-08-12 | Engenes Biotech Gmbh | Uncoupling growth and protein production |
| RU2018138975A (ru) * | 2016-04-06 | 2020-05-12 | Гринлайт Байосайенсис, Инк. | Бесклеточная продукция рибонуклеиновой кислоты |
| US12227778B2 (en) | 2016-12-30 | 2025-02-18 | Nature's Toolbox, Inc. | Cell-free expression system having novel inorganic polyphosphate-based energy regeneration |
| DK3562940T3 (da) | 2016-12-30 | 2022-07-11 | Natures Toolbox Inc | Cellefrit ekspressionssystem med hidtil ukendt, uorganisk polyphosphatbaseret energiregeneration |
| WO2018129275A1 (en) | 2017-01-06 | 2018-07-12 | Greenlight Biosciences, Inc. | Cell-free production of sugars |
| WO2019075167A1 (en) * | 2017-10-11 | 2019-04-18 | Greenlight Biosciences, Inc. | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID |
| WO2022016077A1 (en) | 2020-07-17 | 2022-01-20 | Greenlight Biosciences, Inc. | Nucleic acid therapeutics for genetic disorders |
| EP4304353A4 (en) | 2021-03-08 | 2025-02-12 | Greenlight Biosciences, Inc. | RNA-BASED CONTROL OF POWDERY MILDEW |
| WO2024132094A1 (en) | 2022-12-19 | 2024-06-27 | Thermo Fisher Scientific Geneart Gmbh | Retrieval of sequence-verified nucleic acid molecules |
Family Cites Families (179)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2844514A (en) | 1953-11-04 | 1958-07-22 | Pabst Brewing Co | Process for the production of nucleotides |
| US3223592A (en) | 1957-09-27 | 1965-12-14 | Yamasa Shoyu Kk | Production of 5'-nucleotides |
| USRE28886E (en) | 1969-08-04 | 1976-06-29 | Kyowa Hakko Kogyo Co., Ltd. | Method for preparing cytidine diphosphate choline |
| JPS4841555B1 (enExample) | 1969-08-04 | 1973-12-07 | ||
| US3950357A (en) | 1974-11-25 | 1976-04-13 | Merck & Co., Inc. | Antibiotics |
| US4006060A (en) | 1974-11-25 | 1977-02-01 | Merck & Co., Inc. | Thienamycin production |
| US4194047A (en) | 1975-11-21 | 1980-03-18 | Merck & Co., Inc. | Substituted N-methylene derivatives of thienamycin |
| US4266034A (en) | 1978-04-14 | 1981-05-05 | Exxon Research And Engineering Company | Method for producing microbial cells and use thereof to produce oxidation products |
| US4248966A (en) | 1979-05-17 | 1981-02-03 | Massachusetts Institute Of Technology | Synthesis of isopenicillin derivatives in the absence of living cells |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4292436A (en) | 1980-06-25 | 1981-09-29 | Merck & Co., Inc. | Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol |
| US4329481A (en) | 1980-06-25 | 1982-05-11 | Merck & Co., Inc. | Process for the preparation of N-protected N-formimidoyl 2-aminoethanethiol |
| US4374772A (en) | 1981-03-19 | 1983-02-22 | Merck & Co., Inc. | Process for the preparation of N-formimidoyl thienamycin and reagents therefor |
| JPS585189A (ja) | 1981-07-01 | 1983-01-12 | Sanraku Inc | 新規なアミドヒドロラ−ゼ |
| JPS58129992A (ja) | 1982-01-26 | 1983-08-03 | Kazutomo Imahori | アデノシン一リン酸をアデノシン三リン酸へ変換する方法 |
| US4460689A (en) | 1982-04-15 | 1984-07-17 | Merck & Co., Inc. | DNA Cloning vector TG1, derivatives, and processes of making |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| EP0202094B1 (en) | 1985-05-13 | 1988-09-21 | Unitika Ltd. | Process for producing physiologically active substance |
| JPS61260895A (ja) | 1985-05-13 | 1986-11-19 | Unitika Ltd | 生理活性物質の製造方法 |
| US5672497A (en) | 1986-03-21 | 1997-09-30 | Eli Lilly And Company | Method for increasing the antibiotic-producing ability of antibiotic-producing microorganisms |
| JPS637788A (ja) | 1986-06-25 | 1988-01-13 | Kanegafuchi Chem Ind Co Ltd | 補酵素の回収方法 |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4950603A (en) | 1987-11-02 | 1990-08-21 | Eli Lilly And Company | Recombinant DNA expression vectors and DNA compounds that encode isopenicillin N synthetase from Streptomyces lipmanii |
| JPH01228473A (ja) | 1988-03-08 | 1989-09-12 | Hikari Kimura | 新規な組み換え体ｄｎａおよびグルタチオンの製造法 |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| US5070020A (en) | 1988-05-09 | 1991-12-03 | Eli Lilly And Company | Recombinant dna expression vectors and dna compounds that encode deacetoxycephalosporin c synthetase |
| US5000000A (en) | 1988-08-31 | 1991-03-19 | University Of Florida | Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| ES2067556T3 (es) | 1988-12-22 | 1995-04-01 | Lilly Co Eli | Vectores de expresion de adn recombinante y compuestos de adn que codifican la actividad isopenicilina n epimerasa (racemasa). |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| IL97000A0 (en) | 1990-01-26 | 1992-03-29 | Lilly Co Eli | Recombinant dna expression vectors and dna compounds that encode isopenicillin n epimerase activity |
| DE4004633A1 (de) | 1990-02-15 | 1991-08-22 | Huels Chemische Werke Ag | Verfahren zur herstellung von hefebiomasse |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| KR0177841B1 (ko) | 1992-01-30 | 1999-04-01 | 나까무라 간노스께 | 시티딘 디인산 콜린의 제조방법 |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5319122A (en) | 1992-11-12 | 1994-06-07 | Merck & Co., Inc. | Process for the preparation of benzylformimidate |
| US6746859B1 (en) | 1993-01-15 | 2004-06-08 | Genetics Institute, Llc | Cloning of enterokinase and method of use |
| ATE242330T1 (de) | 1993-01-15 | 2003-06-15 | Inst Genetics Llc | Klonierung von enterokinase und verfahren zu deren verwendung |
| US5436131A (en) | 1993-04-02 | 1995-07-25 | Merck & Co., Inc. | Color screening assay for identifying inhibitor resistant HIV protease mutants |
| US6080555A (en) | 1995-07-06 | 2000-06-27 | Stanford University | Synthesis of polyketides from diketides |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| KR0131166B1 (ko) | 1994-05-04 | 1998-04-11 | 최차용 | 무세포시스템에서 단백질을 제조하는 방법 |
| GB9410142D0 (en) | 1994-05-20 | 1994-07-06 | Univ Warwick | Carbapenems |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| JPH08196284A (ja) | 1995-01-19 | 1996-08-06 | Canon Inc | 酵素反応素子およびその製造方法、酵素反応器ならびに酵素反応方法 |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| KR100205768B1 (en) | 1996-08-24 | 1999-07-01 | Choongwae Pharm Co | Stereo-selective composition of 4-acetoxyazetidinone |
| GB9622516D0 (en) | 1996-10-29 | 1997-01-08 | Univ Cambridge Tech | Enzymic cofactor cycling |
| CN1104505C (zh) | 1996-11-19 | 2003-04-02 | 雅玛山酱油株式会社 | 5'－三磷酸核苷的制造方法及其应用 |
| US20020160459A1 (en) | 1997-01-14 | 2002-10-31 | Alan Berry | Process for production of n-glucosamine |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US6159693A (en) * | 1998-03-13 | 2000-12-12 | Promega Corporation | Nucleic acid detection |
| DE69938127T2 (de) | 1998-03-30 | 2008-07-24 | Metabolix, Inc., Cambridge | Mikrobielle stämme und verfahren für die herstellung von biomaterialien |
| GB9815666D0 (en) | 1998-07-17 | 1998-09-16 | Smithkline Beecham Plc | Novel compounds |
| US6566113B1 (en) | 1998-12-24 | 2003-05-20 | Takara Shuzo Co., Ltd. | Polypeptide having cellobiohydrolase activity |
| US6613552B1 (en) | 1999-01-29 | 2003-09-02 | Board Of Trustees Operating Michigan State University | Biocatalytic synthesis of shikimic acid |
| AU4325900A (en) | 1999-03-17 | 2000-10-04 | Board Of Trustees Of The Leland Stanford Junior University | In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system |
| US6168931B1 (en) | 1999-03-17 | 2001-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced in vitro synthesis of biological macromolecules using a novel ATP regeneration system |
| US6994986B2 (en) | 1999-03-17 | 2006-02-07 | The Board Of Trustees Of The Leland Stanford University | In vitro synthesis of polypeptides by optimizing amino acid metabolism |
| RU2169154C2 (ru) | 1999-03-25 | 2001-06-20 | Институт белка РАН | Способ получения полипептидов в бесклеточной системе |
| IL129427A0 (en) | 1999-04-13 | 2000-02-17 | Yeda Res & Dev | Preparation of biologically active molecules |
| WO2000062804A2 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Identification of sortase gene |
| US6284483B1 (en) | 1999-10-06 | 2001-09-04 | Board Of Trustees Operating Michigan State University | Modified synthetases to produce penicillins and cephalosporins under the control of bicarbonate |
| WO2001046396A1 (en) | 1999-12-21 | 2001-06-28 | Rna-Line Oy | Rna polymerases from bacteriophage phi 6-phi 14 and use thereof |
| CA2293852A1 (fr) | 1999-12-30 | 2001-06-30 | Purecell Technologies Inc. | Procede de preparation d'extraits de plantes actifs et utiles a la capture de radicaux libres; les extraits, et compositions et dispositifs les comprenant |
| EP1264894A4 (en) | 2000-01-17 | 2005-11-30 | Satake Eng Co Ltd | REACTION SYSTEMS FOR ATP REGENERATION AND METHOD FOR THE CONTROL OF ADENIN NUCLEOTIDES, METHOD FOR THE DETECTION OF RNA AND METHOD FOR THE AMPLIFICATION OF ATP USING THEREOF |
| WO2001066705A1 (en) | 2000-03-07 | 2001-09-13 | Akzo Nobel N.V. | Rna polymerase mutants with increased thermostability |
| US7041479B2 (en) | 2000-09-06 | 2006-05-09 | The Board Of Trustess Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| US6548276B2 (en) | 2000-09-06 | 2003-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced in vitro synthesis of active proteins containing disulfide bonds |
| WO2002024902A1 (en) | 2000-09-19 | 2002-03-28 | Eiken Kagaku Kabushiki Kaisha | Method of synthesizing polynucleotide |
| EP2039774A1 (en) | 2001-04-04 | 2009-03-25 | Genencor International, Inc. | Methods for the production of products in host cells |
| US7112434B2 (en) | 2001-05-02 | 2006-09-26 | University Of South Florida | Vector system for selection of genes encoding secreted proteins and membrane-bound proteins |
| EP1279736A1 (en) | 2001-07-27 | 2003-01-29 | Université de Nantes | Methods of RNA and protein synthesis |
| AU2002365425A1 (en) | 2001-08-06 | 2003-09-02 | Vanderbilt University | An apparatus and methods for using biological material to discriminate an agent |
| JPWO2003027301A1 (ja) | 2001-09-06 | 2005-01-06 | 味の素株式会社 | 微生物を用いたアルコールの製造法 |
| BR0212886A (pt) | 2001-09-13 | 2004-10-13 | Genentech Inc | Célula bacteriana, método para a produção de um polipeptìdeo heterólogo, método para a prevenção de clivagem, métodos para a clivagem e métodos para a produção de um polipeptìdeo clivado |
| WO2003038117A2 (en) | 2001-10-30 | 2003-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced in vitro nucleic acid synthesis using nucleoside monophosphates |
| CN2563643Y (zh) | 2001-12-28 | 2003-07-30 | 深圳市华美龙防伪网络系统有限公司 | 动态变码电子防伪装置 |
| US20040038250A1 (en) | 2002-04-04 | 2004-02-26 | Astur-Pharma, S.A. | Gene cluster for thienamycin biosynthesis, genetic manipulation and utility |
| DE10219714A1 (de) | 2002-05-02 | 2003-11-27 | Holland Sweetener Co | Verfahren zur mikrobielien Herstellung von aromatischen Aminosäuren und anderen Metaboliten des aromatischen Aminosäurebiosyntheseweges |
| CN100513576C (zh) | 2002-05-08 | 2009-07-15 | 协和发酵生化株式会社 | 胞苷5’-二磷酸胆碱的制备方法 |
| CA2499885C (en) | 2002-05-29 | 2010-04-20 | Yamasa Corporation | Novel polyphosphate:amp phosphotransferase |
| CN105039464A (zh) | 2002-07-01 | 2015-11-11 | 阿基昂生命科学公司,以生物技术资源部的名义经营 | 用于生产葡糖胺和n-乙酰氨基葡糖的方法和物质 |
| DE60329692D1 (de) | 2002-08-19 | 2009-11-26 | Univ R | Verbesserte verfahren zur in-vitro-proteinsynthese |
| JP4786525B2 (ja) | 2003-01-27 | 2011-10-05 | ディーエスエム アイピー アセッツ ビー．ブイ． | ５’−リボヌクレオチドの製造 |
| CA2520604A1 (en) | 2003-05-09 | 2004-11-25 | Research Development Foundation | Insertion of furin protease cleavage sites in membrane proteins and uses thereof |
| US20080199915A1 (en) | 2003-06-06 | 2008-08-21 | Rna-Line Oy | Methods and Kits For Mass Production Of Dsrna |
| US20050054044A1 (en) | 2003-07-18 | 2005-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method of alleviating nucleotide limitations for in vitro protein synthesis |
| US7341852B2 (en) | 2003-07-18 | 2008-03-11 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of decoupling reaction scale and protein synthesis yield in batch mode |
| JP2007506430A (ja) | 2003-09-23 | 2007-03-22 | ユニヴァーシティー オブ ミズーリ | 耐熱性酵素を使用するポリヌクレオチド合成方法 |
| WO2005030949A1 (en) | 2003-09-24 | 2005-04-07 | Board Of Trustees Operating Michigan State University | Methods and materials for the production of shikimic acid |
| EP1685240B1 (en) | 2003-11-20 | 2014-12-31 | The Board of Trustees of the Leland Stanford Junior University | Improved methods of in vitro protein synthesis |
| JP2005160446A (ja) | 2003-12-05 | 2005-06-23 | Toyobo Co Ltd | 改良されたｒｎａ合成用反応組成物 |
| US20080021205A1 (en) * | 2003-12-11 | 2008-01-24 | Helen Blau | Methods and Compositions for Use in Preparing Hairpin Rnas |
| KR101229849B1 (ko) | 2004-03-25 | 2013-02-05 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 소포제의 첨가에 의한 무세포 단백질 합성 시스템의 단백질발현 수율 개선 방법 |
| DE602005022188D1 (de) | 2004-04-27 | 2010-08-19 | Archer Daniels Midland Co | Enzymatische decarboxylierung von 2-keto-l-gulonsäure zur herstellung von xylose |
| ATE449183T1 (de) | 2004-06-25 | 2009-12-15 | Kyowa Hakko Bio Co Ltd | Verfahren zur herstellung von dipeptiden oder dipeptidderivaten. |
| MX2007006780A (es) | 2004-12-10 | 2007-08-06 | Dsm Ip Assets Bv | Produccion de beta-lactamas en celulas individuales. |
| WO2006090385A2 (en) | 2005-02-22 | 2006-08-31 | Ramot At Tel-Aviv University Ltd. | Protease inhibitors and method of screening thereof |
| JPWO2006109751A1 (ja) | 2005-04-08 | 2008-11-20 | 国立大学法人京都大学 | 無細胞タンパク質合成系によるタンパク質の製造方法 |
| US7351563B2 (en) | 2005-06-10 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free extracts and synthesis of active hydrogenase |
| US7312049B2 (en) | 2005-06-14 | 2007-12-25 | The Board Of Trustees Of The Leland Stanford Junior University | Total amino acid stabilization during cell-free protein synthesis |
| TW200741005A (en) | 2005-08-10 | 2007-11-01 | Kyowa Hakko Kogyo Kk | A purification method of cytidine diphosphate |
| CN1329506C (zh) | 2005-09-06 | 2007-08-01 | 清华大学 | 一种具有颗粒状甲烷单加氧酶活性的重组菌及其应用 |
| US7517680B2 (en) | 2005-09-09 | 2009-04-14 | Johns Hopkins University | Production of clavulanic acid by genetic engineering of Streptomyces clavuligerus |
| CA2626061A1 (en) | 2005-10-31 | 2007-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-free synthesis of membrane bound polypeptides |
| JP4961544B2 (ja) | 2005-11-28 | 2012-06-27 | 国立大学法人広島大学 | 大腸菌を用いたリン酸化反応方法 |
| US7579005B2 (en) | 2005-11-28 | 2009-08-25 | E. I. Du Pont De Nemours And Company | Process for recombinant expression and purification of antimicrobial peptides using periplasmic targeting signals as precipitable hydrophobic tags |
| GB0606112D0 (en) | 2006-03-28 | 2006-05-03 | Product and process | |
| WO2007137144A2 (en) | 2006-05-17 | 2007-11-29 | University Of Medicine And Dentistry Of New Jersey | Single protein production in living cells facilitated by a messenger rna interferase |
| US7846712B2 (en) | 2006-06-01 | 2010-12-07 | Alliance For Sustainable Energy, Llc | L-arabinose fermenting yeast |
| WO2007140816A1 (en) | 2006-06-09 | 2007-12-13 | Metabolic Explorer | Glycolic acid production by fermentation from renewable resources |
| WO2007144018A1 (en) | 2006-06-12 | 2007-12-21 | Metabolic Explorer | Ethanolamine production by fermentation |
| WO2008002661A2 (en) | 2006-06-28 | 2008-01-03 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion protein constructs |
| US20110129438A1 (en) | 2006-06-28 | 2011-06-02 | James Robert Swartz | Immunogenic protein constructs |
| EP2035554B1 (en) | 2006-06-29 | 2013-04-24 | The Board of Trustees of The Leland Stanford Junior University | Cell-free synthesis of proteins containing unnatural amino acids |
| US20090317861A1 (en) | 2006-06-29 | 2009-12-24 | Bundy Bradley C | Cell-free synthesis of virus like particles |
| US8293894B2 (en) | 2006-11-20 | 2012-10-23 | Orchid Chemicals & Pharmaceuticals Limited | Process for the preparation of carbapenem antibiotic |
| WO2008072920A1 (en) | 2006-12-15 | 2008-06-19 | Biofuelchem Co., Ltd. | Method for preparing butanol through butyryl-coa as an intermediate using bacteria |
| KR100832740B1 (ko) | 2007-01-17 | 2008-05-27 | 한국과학기술원 | 분지쇄 아미노산 생성능이 개선된 변이 미생물 및 이를이용한 분지쇄 아미노산의 제조방법 |
| WO2008088884A2 (en) | 2007-01-18 | 2008-07-24 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced cell-free synthesis of active proteins containing disulfide bonds |
| WO2008094546A2 (en) | 2007-01-31 | 2008-08-07 | The Regents Of The University Of California | Genetically modified host cells for increased p450 activity levels and methods of use thereof |
| US20090124012A1 (en) | 2007-08-08 | 2009-05-14 | Mazef Biosciences, Llc | Toxin/antitoxin systems and methods for regulating cellular growth, metabolic engineering and production of recombinant proteins |
| WO2009102205A1 (en) | 2008-02-14 | 2009-08-20 | Wageningen Universiteit | Nucleotide sequences coding for cis-aconitic decarboxylase and use thereof |
| CA3081506A1 (en) | 2008-03-05 | 2009-09-11 | Genomatica, Inc. | Long chain alcohol-producing organisms |
| CA2722680A1 (en) | 2008-05-01 | 2009-11-05 | Genomatica, Inc. | Microorganisms for the production of methacrylic acid |
| CN102089421B (zh) | 2008-07-28 | 2013-06-19 | 科莱恩金融(Bvi)有限公司 | 生产方法 |
| GB0819563D0 (en) | 2008-10-24 | 2008-12-03 | Isis Innovation | Methods for preparing heterocyclic rings |
| AU2009320163B2 (en) | 2008-10-27 | 2014-10-02 | Butamax(Tm) Advanced Biofuels Llc | Carbon pathway optimized production hosts for the production of isobutanol |
| BRPI0921734A2 (pt) | 2008-10-31 | 2019-01-08 | California Inst Of Techn | micro-organismos criados geneticamente capazes de produzir compostos-alvo sob condições anaeróbicas |
| EP2376619A4 (en) | 2008-12-15 | 2012-07-04 | Greenlight Biosciences Inc | METHODS FOR CONTROLLING FLOWS IN METABOLIC PATHWAYS |
| KR20110134380A (ko) | 2008-12-22 | 2011-12-14 | 그린라이트 바이오사이언시스, 아이엔씨. | 화합물의 제조를 위한 조성물 및 방법 |
| EP2204453B1 (en) | 2008-12-30 | 2013-03-13 | Süd-Chemie IP GmbH & Co. KG | Process for cell-free production of chemicals |
| US8597923B2 (en) | 2009-05-06 | 2013-12-03 | SyntheZyme, LLC | Oxidation of compounds using genetically modified Candida |
| US8272816B2 (en) | 2009-05-12 | 2012-09-25 | TDY Industries, LLC | Composite cemented carbide rotary cutting tools and rotary cutting tool blanks |
| WO2010141468A1 (en) | 2009-06-01 | 2010-12-09 | Way Jeffrey C | Methods and molecules for yield improvement involving metabolic engineering |
| BR112012002643A2 (pt) | 2009-08-05 | 2018-08-28 | Genomatica Inc | ácido tereftalático semissintético por meio de micro-organismos que produzem ácido mucônico |
| US9139588B2 (en) | 2009-12-11 | 2015-09-22 | The Johns Hopkins University | Method for late introduction of the (8R)-hydroxyl group carbapenem β-lactam antibiotic synthesis |
| US9040253B2 (en) | 2010-04-14 | 2015-05-26 | Sutro Biopharma, Inc. | Method for enhancing recombinant protein production by cell-free protein expression system |
| US9193959B2 (en) | 2010-04-16 | 2015-11-24 | Roche Diagnostics Operations, Inc. | T7 RNA polymerase variants with enhanced thermostability |
| CA2797786C (en) | 2010-05-07 | 2020-09-22 | Greenlight Biosciences, Inc. | Methods for control of flux in metabolic pathways through enzyme relocation |
| RU2435862C1 (ru) | 2010-06-15 | 2011-12-10 | Общество с ограниченной ответственностью "ВИТАЛАНГ" | Способ получения высокополимерной рнк из отработанных пивных дрожжей |
| ES2839424T3 (es) * | 2010-08-31 | 2021-07-05 | Greenlight Biosciences Inc | Métodos para control de flujo en vías metabólicas mediante manipulación de proteasas |
| WO2012135902A1 (en) | 2011-04-08 | 2012-10-11 | James Cook University | Protease activity assay |
| JP5800218B2 (ja) | 2011-07-20 | 2015-10-28 | 国立大学法人広島大学 | Ａｔｐの製造方法およびその利用 |
| WO2013036787A2 (en) | 2011-09-09 | 2013-03-14 | Greenlight Biosciences, Inc. | Cell-free preparation of carbapenems |
| JP2016504034A (ja) | 2012-12-21 | 2016-02-12 | グリーンライト バイオサイエンシーズ インコーポレーテッドＧｒｅｅｎｌｉｇｈｔ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | メタンを燃料、ピルビン酸またはイソブタノールに変換する無細胞システム |
| WO2014110205A1 (en) | 2013-01-11 | 2014-07-17 | Children's Medical Center Corporation | Methods and compositions for the production of sirnas |
| US9580705B2 (en) | 2013-03-15 | 2017-02-28 | Butamax Advanced Biofuels Llc | DHAD variants and methods of screening |
| KR102530901B1 (ko) | 2013-03-15 | 2023-05-11 | 몬산토 테크놀로지 엘엘씨 | Rna의 생산 및 전달을 위한 조성물 및 방법 |
| CA2914504C (en) | 2013-06-05 | 2019-04-16 | Zhiguang ZHU | Complete oxidation of sugars to electricity by using cell-free synthetic enzymatic pathways |
| SG11201509976TA (en) | 2013-06-05 | 2016-01-28 | Greenlight Biosciences Inc | Control of metabolic flux in cell-free biosynthetic systems |
| SG11201600898YA (en) | 2013-08-05 | 2016-03-30 | Greenlight Biosciences Inc | Engineered proteins with a protease cleavage site |
| CL2014003146A1 (es) | 2014-11-20 | 2015-06-12 | Univ Santiago Chile | Método para producir virus arn monocatenario negativo; plásmido recombinante funcional en células animales, que consta de un esqueleto pss-urg; método de obtención de partículas virales; y uso para expresar arn, proteínas autógenas o exógenas al virus. |
| US20180273985A1 (en) | 2015-03-19 | 2018-09-27 | William Jeremy Blake | Cell-free production of butanol |
| EP3277808A4 (en) | 2015-03-30 | 2019-05-22 | Greenlight Biosciences, Inc. | ACELLULAR PRODUCTION OF RIBONUCLEIC ACID |
| CN105219822A (zh) | 2015-09-24 | 2016-01-06 | 北京化工大学 | 一种体外酶法生产谷胱甘肽的方法 |
| RU2018138975A (ru) | 2016-04-06 | 2020-05-12 | Гринлайт Байосайенсис, Инк. | Бесклеточная продукция рибонуклеиновой кислоты |
| DK3562940T3 (da) | 2016-12-30 | 2022-07-11 | Natures Toolbox Inc | Cellefrit ekspressionssystem med hidtil ukendt, uorganisk polyphosphatbaseret energiregeneration |
| WO2018129275A1 (en) | 2017-01-06 | 2018-07-12 | Greenlight Biosciences, Inc. | Cell-free production of sugars |
| WO2019075167A1 (en) | 2017-10-11 | 2019-04-18 | Greenlight Biosciences, Inc. | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID |
-
2016
- 2016-03-30 EP EP16774076.0A patent/EP3277808A4/en not_active Withdrawn
- 2016-03-30 CA CA2980172A patent/CA2980172A1/en active Pending
- 2016-03-30 MX MX2017012665A patent/MX392776B/es unknown
- 2016-03-30 MY MYPI2017703491A patent/MY193444A/en unknown
- 2016-03-30 SG SG11201707370WA patent/SG11201707370WA/en unknown
- 2016-03-30 US US15/562,456 patent/US11274284B2/en active Active
- 2016-03-30 CR CR20170485A patent/CR20170485A/es unknown
- 2016-03-30 KR KR1020177031307A patent/KR20180002636A/ko not_active Abandoned
- 2016-03-30 RU RU2017137788A patent/RU2017137788A/ru not_active Application Discontinuation
- 2016-03-30 CN CN201680019707.4A patent/CN107614682B/zh not_active Expired - Fee Related
- 2016-03-30 KR KR1020237010502A patent/KR20230048162A/ko not_active Ceased
- 2016-03-30 AU AU2016243623A patent/AU2016243623B2/en not_active Ceased
- 2016-03-30 WO PCT/US2016/024937 patent/WO2016160936A1/en not_active Ceased
- 2016-03-30 JP JP2017551594A patent/JP6843065B2/ja not_active Expired - Fee Related
- 2016-03-30 BR BR112017020690A patent/BR112017020690A2/pt not_active Application Discontinuation
-
2017
- 2017-09-11 IL IL254413A patent/IL254413B/en unknown
- 2017-09-26 CL CL2017002427A patent/CL2017002427A1/es unknown
-
2021
- 2021-02-22 JP JP2021026113A patent/JP2021100406A/ja active Pending
-
2022
- 2022-02-02 US US17/591,514 patent/US20220403355A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180002636A (ko) | 2018-01-08 |
| JP2021100406A (ja) | 2021-07-08 |
| MY193444A (en) | 2022-10-13 |
| RU2017137788A (ru) | 2019-04-30 |
| EP3277808A1 (en) | 2018-02-07 |
| CR20170485A (es) | 2018-02-05 |
| KR20230048162A (ko) | 2023-04-10 |
| MX392776B (es) | 2025-03-11 |
| IL254413B (en) | 2021-12-01 |
| WO2016160936A1 (en) | 2016-10-06 |
| IL254413A0 (en) | 2017-11-30 |
| BR112017020690A2 (pt) | 2018-06-26 |
| AU2016243623A1 (en) | 2017-10-05 |
| US20220403355A1 (en) | 2022-12-22 |
| SG11201707370WA (en) | 2017-10-30 |
| MX2017012665A (es) | 2018-04-24 |
| CL2017002427A1 (es) | 2018-04-13 |
| US11274284B2 (en) | 2022-03-15 |
| JP2018509927A (ja) | 2018-04-12 |
| EP3277808A4 (en) | 2019-05-22 |
| CA2980172A1 (en) | 2016-10-06 |
| US20180087045A1 (en) | 2018-03-29 |
| CN107614682B (zh) | 2021-11-09 |
| CN107614682A (zh) | 2018-01-19 |
| AU2016243623B2 (en) | 2022-04-14 |
| RU2017137788A3 (enExample) | 2020-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6843065B2 (ja) | リボ核酸の無細胞生産 | |
| JP7011599B2 (ja) | リボ核酸の無細胞的生産 | |
| KR102894284B1 (ko) | 뉴클레오시드 트리포스페이트 및 리보핵산 생산을 위한 방법 및 조성물 | |
| RU2777282C2 (ru) | Способы и композиции для получения нуклеозидтрифосфата и рибонуклеиновой кислоты | |
| HK40104450A (en) | Cell-free production of ribonucleic acid | |
| BR112018070506B1 (pt) | Método isento de células para a síntese de ácido ribonucleico | |
| BR122024025160A2 (pt) | Método isento de células para a síntese de ácido ribonucleico | |
| NZ786906A (en) | Cell-free production of ribonucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190325 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200122 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200430 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210121 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210222 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6843065 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |